C4 Therapeutics, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
C4 Therapeutics, Inc. (CCCC) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $665.00 thousand as of 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2024-02-22
- 2023-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $665.00K.
- 2023-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $129.00K.
- 2022-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.02M.
- 2022-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.20M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2023-06-30 | $665.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $129.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.02M 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.20M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.38M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.56M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.73M 10-K · filed 2022-02-24 |
| 2021-09-30 | $1.91M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $2.09M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $2.27M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $2.45M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |